Oner Pinar, Oner Ozgur, Cop Esra, Munir Kerim M
Department of Child and Adolescent Psychiatry, Dr. Sami Ulus Childrens' Hospital, Ankara - Turkey.
Fogarty International Center Mental Health and Developmental Disabilities Program, Children's Hospital, Boston, MA, USA.
Klinik Psikofarmakol Bulteni. 2012;22(4):325-331. doi: 10.5455/bcp.20120403015900. Epub 2016 Nov 8.
Several studies have shown that iron deficiency and ferritin levels are associated with parent and teacher Attention Deficit Hyperactivity Disorder (ADHD) ratings. Although there are conflicting results, it has also been reported that iron supplementation may help to decrease ADHD symptoms. When all these previous studies are taken into account, it is clear that a large study investigating the effects of iron deficiency and ferritin levels on routine pharmacological treatment of ADHD with stimulants would be helpful to elucidate this treatment from a clinical point of view.
A total of 345 subjects with combined or predominantly hyperactive-impulsive (PHI) subtypes of ADHD were included. All diagnoses were based on the DSM-IV criteria and ascertained by direct interviews conducted by the authors, who are experienced child psychiatrists certified in the use of the Schedule for Affective Disorders and Schizophrenia for School-Age Children - Present and Lifetime Version (K-SADS-PL) semi-structured interview. The two treatment response criteria were: 1) 25% or more decrease in pre-treatment Conners Parent Rating Scale (CPRS) and Conners Teacher Rating Scale (CTRS) Hyperactivity (HA) and Total Problems scores; 2) CPRS and CTRS HA scores lower than the cut-off point ("very improved").
A total of 255 (73.9%) patients were on OROS-methylphenidate (OROS-MPH) and 90 (26.1%) were on immediate release methylphenidate (IR-MPH). The mean±sd of OROS-MPH and IR-MPH doses were 28.8±8.1 and 20.9±7.1 mg, respectively. More than half (52.5%) of the subjects were previously drug-naive at treatment inception. Two hundred and seventy eight (80.6%) subjects had combined subtype ADHD and the remainder had predominantly hyperactive-impulsive subtype. Only 60 (17.4%) of the subjects had no comorbid disorders, while 38.3% had one comorbid disorder, 32.8% had two comorbid disorders, and 11.6% had three or more comorbid disorders. The most frequent comorbidity was Oppositional Defiant Disorder/Conduct Disorder (ODD/CD, 51.6%), followed by Learning Disabilities (LD, 35.4%) and Anxiety Disorders (AD, 15.9%). Logistic regression analysis showed that subjects with comorbid ODD/CD and LD were less likely to respond to treatment. Ferritin levels and iron deficiency were not associated significantly with outcomes.
In a large sample of subjects with combined or predominantly hyperactive-impulsive subtypes of ADHD, after controlling for several factors, we found that neither iron deficiency (ferritin <12 ng/ml) nor ferritin levels were associated with less favorable short-term treatment outcomes with stimulants. Subjects with comorbid ODD/CD and LD were less likely to have a 25% or more decrease in CTRS Total score. The presence of ODD/CD was also a negative predictor of treatment response in terms of CPRS Total and HA scores. The lack of a negative treatment response in ADHD subjects with iron deficiency and lack of a negative association with ferritin levels suggest that the relationship between iron metabolism and ADHD, a highly heterogeneous disorder, may be more complicated than previously believed.
多项研究表明,缺铁及铁蛋白水平与家长及教师对注意力缺陷多动障碍(ADHD)的评分相关。尽管结果存在矛盾,但也有报道称补充铁剂可能有助于减轻ADHD症状。综合以往所有这些研究来看,显然开展一项大型研究来调查缺铁及铁蛋白水平对ADHD常规兴奋剂药物治疗的影响,将有助于从临床角度阐明这种治疗方法。
共纳入345例患有ADHD合并型或主要为多动冲动型(PHI)亚型的受试者。所有诊断均基于《精神疾病诊断与统计手册》第四版(DSM-IV)标准,并由作者通过直接访谈确定,作者均为经验丰富的儿童精神科医生,通过使用《学龄儿童情感障碍和精神分裂症量表 - 当前及终生版》(K-SADS-PL)半结构化访谈获得认证。两个治疗反应标准为:1)治疗前康纳斯家长评定量表(CPRS)和康纳斯教师评定量表(CTRS)中的多动(HA)及总问题得分降低25%或更多;2)CPRS和CTRS的HA得分低于临界点(“显著改善”)。
共有255例(73.9%)患者服用缓释哌甲酯(OROS-MPH),90例(26.1%)患者服用速释哌甲酯(IR-MPH)。OROS-MPH和IR-MPH剂量的均值±标准差分别为28.8±8.1和20.9±7.1毫克。超过一半(52.5%)的受试者在治疗开始时未曾使用过药物。278例(80.6%)受试者患有ADHD合并型,其余受试者主要为多动冲动型。只有60例(17.4%)受试者无共病,而38.3%的受试者有一种共病,32.8%的受试者有两种共病,11.6%的受试者有三种或更多共病。最常见的共病是对立违抗障碍/品行障碍(ODD/CD,51.6%),其次是学习障碍(LD,35.4%)和焦虑障碍(AD,15.9%)。逻辑回归分析表明,患有ODD/CD和LD共病的受试者对治疗的反应较小。铁蛋白水平和缺铁与治疗结果无显著关联。
在一大组患有ADHD合并型或主要为多动冲动型亚型的受试者中,在控制了多个因素后,我们发现缺铁(铁蛋白<12纳克/毫升)和铁蛋白水平均与兴奋剂短期治疗效果不佳无关。患有ODD/CD和LD共病的受试者CTRS总分降低25%或更多的可能性较小。就CPRS总分和HA得分而言,ODD/CD的存在也是治疗反应的负面预测因素。缺铁的ADHD受试者缺乏负面治疗反应且与铁蛋白水平无负相关,这表明铁代谢与ADHD(一种高度异质性疾病)之间的关系可能比之前认为的更为复杂。